Skip to content
‹ Back to IndustriesHealthcare

Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere from hospitals, nursing homes, restaurants, hotels, gyms to commercial office spaces, tourist attractions, and professional sports stadiums. Surfacide has been a trusted leader in UV decontamination for over ten years due to its world’s only patented Helios® Triple-Emitter System of three virus-zapping robots.

Surfacide is actively being used throughout the world in over 500 leading healthcare facilities, children’s hospitals, nursing homes, correctional facilities, dental offices, hotels, restaurants, commercial businesses and more around the world. Such facilities include the Seattle Space Needle, Beachbody Studios, Children’s Hospital of Los Angeles and locally at Children’s Hospital of Wisconsin, Froedtert Medical College—Milwaukee and Aspirus Wausau Hospital. The company’s UV-C technology is scientifically validated to inactivate coronavirus–the family of virus that make up SARS-CoV-2 and COVID-19.

Surfacide’s new location is at N918 Northmound Dr., STE. 300 Waukesha, WI 53186 and the company’s new facility is more than 75,000 sq-ft, three times the size of their previous location. The company was started in a one-room office in 2010 and has experienced incredible and consistent growth every year since its inception. The expansive new building space will offer much needed space for Surfacide’s expanding team and to meet the huge increase in demand for their UV system since the pandemic hit. The facility will continue to house the company’s manufacturing and distribution arm, as well as a global training center, a state-of-the-art UV robot simulation room, conference rooms and offices.

Gunner Lyslo, Founder & CEO of Surfacide shares his excitement for the new space: “During the pandemic, we are fortunate to have grown our team and provide a proven UV-C technology that has tremendously impacted healthcare facilities, nursing homes, dental offices, and more in fighting the COVID-19 virus,” says Lyslo. “This year the importance of infection prevention has been paramount, and we expect to see that course continue in years to come. For as long as our communities need safety and protection, Surfacide will continue to evolve and be there to assist those who need it most.”

 About Surfacide

 Surfacide LLC and Surfacide Manufacturing Inc. are located in Waukesha, WI and produce multiple emitter UV-C systems. Surfacide is the only patented triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and bacteria that cause hospital-acquired infections. Hundreds of hospitals worldwide are using Surfacide technology to provide an extra layer of protection for patients and healthcare workers. Surfacide’s evidence-based UV-C solution reaches more surfaces, reduces shadowed areas, and requires less labor for a quicker turnaround time and better efficacy. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

AI cuts cardiologists' echocardiogram review time by 46%

AI cuts cardiologists' echocardiogram review time by 46%

Late-breaking research presented November 9 at the American Heart Association's Scientific Sessions 2026 reported that AI-drafted preliminary echocardiogram reports were comparable to human drafts. Cardiologists averaged 4.6 minutes finalizing AI drafts versus 8.5 minutes without AI. The findings are a non-peer-reviewed abstract.

  • 01Cardiologists averaged 4.6 minutes finalizing AI-drafted echo reports versus 8.5 minutes without AI, about 46% less time.
  • 02Cardiologists made substantial changes to 50.6% of AI drafts and 49.7% of human drafts.
  • 03The research used 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centers.

Nov 9, 2026

After Chicago: Did AI at AHA 2026 Pass Its Own Test?

After Chicago: Did AI at AHA 2026 Pass Its Own Test?

At AHA Scientific Sessions 2026 in Chicago, AI ECHO INSIGHT, WATCH-LV, PARAMOUNT and PROVAR+ showed gains in workflow efficiency, screening and treatment decisions, but none established a reduction in hard clinical events. The takeaway: the next test is proving these tools improve outcomes, especially in high-need populations, by connecting to established care.

  • 01AI ECHO INSIGHT cut echo reads 8.5 to 4.6 minutes, and PARAMOUNT changed treatment decisions, but no AI late-breaker showed fewer hard events.
  • 02ZEUS and Lp(a)HORIZON lowered their target biomarkers without reducing major cardiovascular events, a caution against treating algorithmic accuracy alone as proof of patient benefit.
  • 03Low-technology, team-based interventions such as CATCH in Colombia and Jamaica lowered blood pressure, showing the care systems AI tools must connect to.

Nov 9, 2026

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Access TeleCare pharmacist Ashley Selby describes a telehealth antimicrobial stewardship model sized to each hospital's gaps. Joint Commission Standard MM.09.01.01 and 42 CFR 482.42 require a qualified physician and/or pharmacist leader, not a full-time hire, and a 14-study meta-analysis found telehealth stewardship cut antibiotic days of therapy without changing mortality.

  • 01Joint Commission Standard MM.09.01.01, in force since January 2023, requires a physician and/or pharmacist qualified in infectious diseases or stewardship to lead the program, and its committee note allows remote participation.
  • 02The Board of Pharmacy Specialties counts more than 2,380 BCIDP pharmacists nationally, while many small hospitals still assign stewardship to pharmacists without ID training.
  • 03A 14-study meta-analysis found telehealth stewardship raised guideline adherence and cut antibiotic days of therapy, but did not significantly change mortality.

Nov 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512